Jagsonpal Pharmaceuticals reverberates the fearless conviction and vision of its founder
Mr. Jagmohan S Kochhar. It chronicles the odyssey from a humble chemist store in Delhi that went on to become one of India’s premier multi-national pharma success stories.
Our founder’s vision to make it a leading pharmaceutical company with a focus on serving humanity with affordable and quality healthcare has been a driving force for the Company’s success.
Jagsonpal Pharmaceuticals Limited is a Delhi-based pharmaceutical company
Founded in 1978, the Company has a proven track record of 40+ years catering to the Indian pharmaceutical market. It has a robust portfolio of drugs focusing on the Gynaecology and Orthopaedic segments
Over the years, the Company has successfully built multiple brands that today hold market-leading position in respective segments. It has created a niche in these value-accretive segments by establishing a presence across all major sub-segments
We at Jagsonpal work on a strong foundation of safety, responsibility, trust and integrity. This has helped us collaborate with partners who resonate with our core values to build an organisation that relentlessly works towards innovative solutions for affordable and quality healthcare.
We take immense pride in our legacy and our mission to create a global brand from India - truly “atma-nirbhar”. This has been possible only because of the relentless support of our employees, our truest wealth.
We have been serving the world for over five decades and it is our endeavour to stay committed towards value creation and continue in the same trajectory.
Board of Directors
Mr. Manish Gupta
Mr. Manish Gupta has a well-established track record of successfully leading and managing businesses across the globe. His last stint was with SeQuent Scientific Limited (SeQuent) as the CEO and Managing Director for 8 years. Previously, he has been the CEO – Pharma Business for Strides Pharma Science.
Mr. Gupta led SeQuent since 2014 and played a major role in transforming the Company from a small India-focused business to a global organization with operations in India, Turkey, Brazil and EU, emerging as India’s largest and ‘top 20’ global animal health company. He undertook a series of structural moves including inorganic initiatives with emphasis on consolidating market presence, entering new markets, and strengthening customer-centricity.
Prior to that, he was associated with Wockhardt in various capacities with his last role being as the Managing Director of Pinewood Healthcare, Ireland and CEO of Radiant Research, a CRO in USA.
Mr. Harsha Raghavan
Mr. Harsha Raghavan, based in Mumbai, is the Managing Partner of Convergent Finance LLP. Mr. Raghavan was previously the founding MD & CEO of Fairbridge Capital Private Limited (a Fairfax Company) from its inception in 2011 where he led all investment advisory activities in India. During his time, he sourced and advised on over $2.1 billion worth of investment activity. Previously, he served as Head of India for Candover Investments, Co-Head of India for Goldman Sachs Principal Investment Area, and Vice President of Indocean Chase Capital. In these roles, Mr. Raghavan had advised on more than two dozen transactions totaling over $1.5 billion in value. Mr. Raghavan holds a Master of Business Administration degree and Master of Science degree in industrial engineering both from Stanford University and a Bachelor of Arts degree from the University of California at Berkeley, where he double-majored in computer science and economics.
Mr. Debasis B Nandy
More than thirty years of experience in Manufacturing and Service industry, having worked across domains such as Mergers & Acquisitions, Investor Relations, Accounts & Controlling, Tax, Treasury, Budgeting, Planning and Business Finance
Led Thomas Cook through acquisition by Fairfax in 2012 and the consequent management change. As Vice President-Finance in Piramal Healthcare, he planned & executed activities aimed at enhancing financial strength of the organization
He completed Chartered Accountancy in 1987 and subsequently attended Executive Development Program at Wharton Business School, Philadelphia in May, 2005 and London Business School, in December, 2005
Ms Radhika M Dudhat
She has worked on areas including transaction structuring, strategy formulation, documentation and negotiations for complex and sensitive transactions across matters pertaining to real estate, infrastructure, insolvency and bankruptcy
In legal risk management, she advises on transactional, corporate governance, and regulatory compliances. She also works on matters relating to new business structuring and applicable regulatory and contractual framework
Radhika has been appointed as the Chairperson of Corporate Law and Governance Sub-Committee of IMC Chamber of Commerce & Industry
She is a Graduate from University of Bombay Faculty of Life Sciences, a law graduate from the University of Bombay and a Postgraduate from the University of Cambridge and Harvard University
Ms Pallavi Dinodia Gupta
As a Chartered Accountant, she has worked with multinationals, large Indian families and non-profit organizations while advising on valuation, corporate and tax laws. She is also trained as a lawyer and has worked with numerous businesses over the past two decades
Additionally, she has served on board of listed companies and international organizations. This includes serving as the Chairperson of APAC Region and as a key member of the global governing council for MGI Worldwide – one of the largest global networks of accounting, audit and taxation firms
Mr Prithipal Singh Kochhar
Prithi is the Founder and CEO of Naari CEO which is a company focussed on Women Health. The Company has two development and manufacturing sites in India - for intermediates, APIs and FDFs and offices in Singapore, Ukraine, US and Netherlands. He has successfully expanded operations of the Company in India, South East Asia, Europe, CIS and Africa
Earlier, he founded and served as the CEO of the Indo Phyto Chemicals Pvt Limited for eight years. Starting in 2009 with annual revenue of less than $ 250,000 he was successful in exponentially growing the business before selling majority stake in 2016.